Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA Inc.
| Collegium Pharmaceutical, Inc. |
| Teva Pharmaceuticals USA Inc. |
| 1:2019cv00876 |
| May 9, 2019 |
| US District Court for the District of Delaware |
| Christopher J Burke |
| Leonard P Stark |
| Patent |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 27, 2019. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 11 ANSWER to #8 Answer to Complaint, Counterclaim by Collegium Pharmaceutical, Inc..(Cottrell, Frederick) |
Filing 10
ORAL ORDER: IT IS HEREBY ORDERED that the parties shall meet and confer and discuss, in person and/or by telephone, each of the matters listed on Chief Judge Stark's Case Management Checklist ("Checklist"). Within thirty (30) days from the date of this Order, the parties shall jointly file the following: (i) a copy of the "Checklist" indicating the names of Lead Counsel and Delaware Counsel for each party; (ii) a proposed Scheduling Order consistent with the Chief Judge Stark's Revised Patent Form Scheduling Order (with the exception that Paragraph (g) of the parties' proposed Scheduling Order shall be altered as follows: (a) the letter referenced in Paragraph (g)(ii) should be addressed to Judge Burke; (b) the time frames for the letters referenced in Paragraph (g)(iii) should be changed to 96 hours for the initial letter filed by the movant and 48 hours for the responsive letter filed by the opposing party; and (c) the parties should include an additional requirement that, after the Court has issued an order scheduling the discovery teleconference, the parties shall file a joint "Motion for Teleconference to Resolve Discovery Dispute," the text of which can be found in the "Forms" tab of Judge Burke's page on the District Court's website); and (iii) a letter, not to exceed three pages, that contains the following: (a) a description of what this case is about; (b) the parties' positions regarding the disputes in the proposed Scheduling Order, and (c) a list of the three most significant topics (other than Scheduling Order disputes) discussed during the parties' review of the Checklist items, along with a brief description as to what was discussed as to those topics. Thereafter, the Court will schedule a Case Management Conference/Rule 16 Scheduling Conference to be held with Judge Burke. The Checklist and Revised Patent Form Scheduling Order can be found on this Court's website (www.ded.uscourts.gov/judge/chief-judge-leonard-p-stark). Ordered by Judge Christopher J. Burke on 6/7/2019. (dlb)
|
| Filing 9 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals USA Inc. filed by Teva Pharmaceuticals USA Inc.. (Keller, Karen) |
| Filing 8 ANSWER to #1 Complaint, Affirmative Defenses, And, COUNTERCLAIM against Collegium Pharmaceutical, Inc. by Teva Pharmaceuticals USA Inc..(Keller, Karen) |
| Filing 7 AFFIDAVIT of Service for Complaint for Patent Infringement served on Douglas R. Weider on May 16, 2019, filed by Collegium Pharmaceutical, Inc.. (Attachments: #1 Exhibit A)(Haynes, Christine) |
|
Filing 6
ORAL ORDER REFERRING CASE to Magistrate Judge Christopher J. Burke: IT IS HEREBY ORDERED that the above-captioned case is referred to Magistrate Judge Christopher J. Burke to hear and resolve all pre-trial matters up to and including expert discovery matters (but not including summary judgment motions, Daubert motions, pre-trial motions in limine or the pre-trial conference), subject to 28 U.S.C. 636(b) and any further Order of the Court. All subsequent filings in this action shall be captioned as follows: Civil Action No. 19-876-LPS-CJB. ORDERED by Judge Leonard P. Stark on 5/21/2019. (ntl)
|
| Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (nmg) |
| Filing 5 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 28, 2019. Date of Expiration of Patent: Sepetmber 2, 2036.Thirty Month Stay Deadline: 7/10/2020. (Cottrell, Frederick) |
| Filing 4 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Collegium Pharmaceutical, Inc. (nmg) |
| Filing 3 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,188,644. (nmg) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Filing 1 COMPLAINT for PATENT INFRINGEMENT filed against Teva Pharmaceuticals USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2639091.) - filed by Collegium Pharmaceutical, Inc. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(nmg) |
| No Summons Issued. (nmg) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
